Protara Therapeutics, Inc. 8-K

What Happened

• On March 30, 2026, Protara Therapeutics announced a confirmed six‑month complete response (CR) rate of 68.0% in the 25th BCG‑Unresponsive patient cohort from its ongoing Phase 2 open‑label ADVANCED‑2 trial of TARA‑002 in carcinoma in situ (CIS ± Ta/T1) non‑muscle invasive bladder cancer (NMIBC). This result is consistent with the 68.2% six‑month CR rate the company announced on February 24, 2026 and is substantially above 41.9%.
• Because this clinical threshold was met, Protara determined it satisfied the condition in its April 2024 Common Warrants for fixing the termination date for exercise. The April 2024 Common Warrants are exercisable at $5.25 per share and may be exercised at any time on or prior to June 29, 2026.

Key Details

• Six‑month CR rate in 25 BCG‑Unresponsive patients: 68.0% (consistent with prior 68.2% figure).
• Comparator/threshold referenced: 41.9% (company notes result is meaningfully above this level).
• Warrants: "April 2024 Common Warrants" exercisable at $5.25 per share; termination date fixed as June 29, 2026.
• Disclosure filed as Regulation FD information on March 30, 2026.

Why It Matters

• Clinical update: Confirmed 6‑month CR data is a material clinical milestone for the ADVANCED‑2 Phase 2 program for TARA‑002 and is a key datapoint investors use to assess trial progress and potential regulatory or commercial prospects.
• Capital structure impact: Fixing the warrant termination date creates a defined window (through June 29, 2026) during which warrant holders can exercise at $5.25, which could lead to share issuance and dilution if exercised. Investors and warrant holders now have clarity on the exercise deadline.
• Regulatory disclosure: The information was shared under Regulation FD, meaning the company publicly disclosed material information to ensure fair access to investors.